ParenteralTopicalDosed ingredientTherapeutic flag Cosmetic cross-reference

Testosterone

CAS 58-22-0

Testosterone (CAS 58-22-0) is a Phase 4 pharmaceutical compound with 12 bioactivity targets and 2,892 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
19
SOURCE DrugCentral
Adverse signals
2,892
SOURCE IUPHAR/BPS
PubMed IDs
3
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Testosterone
CAS Number
58-22-0
UNII
3XMK78S47O
InChIKey
MUMGGOZAMZWBJJ-DYKIIFRCSA-N
ChEMBL ID
CHEMBL386630
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
TESTOSTERONE ENANTHATETESTOSTERONE CYPIONATEDepo-testosteroneAndrodermAndrogelTestim
black box warningdosed ingredientnatural productparenteraltherapeutic flagtopical
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL386630 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 19 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 14291.15873015873 nM 63 -
- IC50 7494.844848484849 nM 33 -
- Potency 24257.339393939394 nM 31 -
- Ki 7793.971666666666 nM 15 -
- EC50 3661.6313999999998 nM 5 -
- Kd 0.5155000000000001 nM 2 -
Sigma non-opioid intracellular receptor 1
Membrane receptor
 Ki 5.92 - Homo sapiens
Glucocorticoid receptor
Nuclear hormone receptor
 Ki 5.837 - Homo sapiens
Androgen receptor
Nuclear hormone receptor
 EC50 9.2 - Homo sapiens
Aromatase
Enzyme
 Ki 6.22 - Homo sapiens
Corticosteroid-binding globulin
Secreted
 Ki 6.72 - Homo sapiens
Sex hormone-binding globulin
Secreted
 Kd 9.2 - Homo sapiens
Lanosterol 14-alpha demethylase
Enzyme
 IC50 4.3 - Homo sapiens
Androgen receptor
Transcription factor
 Ki 8.85 - Rattus norvegicus
Progesterone receptor
Transcription factor
 Ki 6.599 - Bos taurus
C-8 sterol isomerase
Enzyme
 Ki 5.11 - Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
Steroid 5-alpha-reductase
Enzyme
 IC50 5.72 - Rattus norvegicus
Constitutive androstane receptor
Nuclear hormone receptor
 IC50 4.52 - Mus musculus
Alpha-synuclein
Transporter
 IC50 4.01 - Homo sapiens
SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Blood testosterone decreased 258 1005.533 10005814
Blood testosterone increased 201 932.032 10005815
Product deposit 116 535.064 10069250
Polycythaemia 140 505.347 10036051
Idiopathic intracranial hypertension 134 446.474 10078904
Expulsion of medication 54 317.272 10074905
Poor quality product administered 104 282.54 10081478
Product administered at inappropriate site 96 251.398 10080753
Precocious puberty 54 250.688 10058084
Multiple use of single-use product 74 225.498 10072342
Blood testosterone abnormal 50 223.058 10005812
Deep vein thrombosis 304 222.062 10051055
Application site rash 74 210.847 10003054
Metaplasia 53 205.143 10054949
Virilism 30 185.328 10047486
Incorrect dose administered 226 170.244 10064355
Haematocrit increased 69 169.126 10018840
Testicular atrophy 39 155.088 10043298
Product quality issue 154 150.207 10069327
Pulmonary embolism 305 148.929 10037377
Erectile dysfunction 98 142.987 10061461
Accidental exposure to product 122 127.82 10073317
Drug abuse 252 124.854 10013654
Hair growth abnormal 51 121.928 10019044
Libido decreased 60 116.138 10024419
Gynaecomastia 65 109.7 10018800
Insulin-like growth factor increased 40 109.47 10059596
Application site pain 55 109.26 10003051
Prostatic disorder 45 106.836 10036956
Application site erythema 56 105.747 10003041
Infertility male 23 104.688 10021929
Enlarged clitoris 22 103.674 10014838
Prostatic specific antigen increased 70 103.527 10036975
Osteonecrosis 107 101.873 10031264
Blood testosterone free decreased 18 94.831 10053786
Mesenteric vein thrombosis 35 92.026 10027402
Product packaging quantity issue 38 91.705 10069299
Clear cell renal cell carcinoma 37 90.095 10073251
Systemic lupus erythematosus 4 90.08 10042945
Product odour abnormal 36 89.474 10069226
Acute myocardial infarction 147 89.453 10000891
Liquid product physical issue 34 89.361 10069224
Toxicity to various agents 53 85.657 10070863
Synovitis 3 85.281 10042868
Contraindicated product administered 11 84.795 10078504
Myocardial infarction 253 82.326 10028596
Renal infarct 35 80.558 10038470
Cervix carcinoma stage IV 16 80.404 10008348
Oestradiol increased 18 80.036 10030231
Focal segmental glomerulosclerosis 37 78.986 10067757

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 1 interaction

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

TargetAction AffinityPubMed
Androgen receptor
Ar
 Agonist 7.8 pIC50 14565775
SOURCE PharmGKB 3 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

UGT1A4 (PA37179) UGT1A4*1a, UGT1A4*2
UGT1A4 *2 is not associated with increased clearance of testosterone as compared to UGT1A4 *1a.
Evidence: -; PMID 22047493
UGT1A4 (PA37179) UGT1A4*1a, UGT1A4*3a
UGT1A4 *3a is associated with increased clearance of testosterone as compared to UGT1A4 *1a.
Evidence: -; PMID 22047493
UGT1A4 UGT1A4*1a, UGT1A4*3a
-
Evidence: 3; PMID 1
SOURCE NLM RxNorm 12 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
testosterone 10379 SU MTHSPL
TESTOSTERONE 10379 SU MTHSPL
Testosterone 10379 SU MTHSPL
TESTOSTERONE ENANTHATE 37859 SU MTHSPL
TESTOSTERONE CYPIONATE 835827 SU MTHSPL
testosterone 10379 IN RXNORM
testosterone enanthate 37859 PIN RXNORM
Depo-testosterone 48877 BN RXNORM
Androderm 215283 BN RXNORM
Androgel 261448 BN RXNORM
Testim 353016 BN RXNORM
testosterone cypionate 835827 PIN RXNORM
SOURCE SIDER 80 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side EffectDrug Name MedDRA TypeConcept ID
Abdominal cramps testosterone LLT C0000729
Abdominal pain testosterone PT C0000737
Abdominal pain testosterone LLT C0000737
Abdominal pain testosterone PT C0000737
Abdominal pain testosterone LLT C0000737
Abdominal pain testosterone PT C0000737
Abdominal pain testosterone LLT C0000737
Abdominal pain testosterone PT C0000737
Abdominal pain testosterone LLT C0000737
Abdominal pain testosterone PT C0000737
Abdominal pain upper testosterone LLT C0232492
Abdominal pain upper testosterone PT C0232492
Abdominal symptom testosterone LLT C0740651
Abdominal symptom testosterone PT C0740651
Abnormal clotting factor testosterone LLT C0877331
Abnormal clotting factor testosterone PT C0877331
Abnormal dreams testosterone LLT C0234458
Abnormal dreams testosterone PT C0234458
Acne testosterone LLT C0702166
Acne testosterone PT C0702166
Acne testosterone LLT C0702166
Acne testosterone PT C0702166
Activated partial thromboplastin time prolonged testosterone LLT C0240671
Activated partial thromboplastin time prolonged testosterone PT C0240671
Acute coronary syndrome testosterone PT C0948089
Administration site reaction testosterone LLT C0851536
Administration site reaction testosterone PT C0851536
Affect lability testosterone PT C0233472
Affect lability testosterone LLT C0233472
Affect lability testosterone PT C0233472
Affective disorder testosterone LLT C0525045
Affective disorder testosterone PT C0525045
Aggression testosterone LLT C0001807
Aggression testosterone PT C0001807
Aggression testosterone LLT C0001807
Aggression testosterone PT C0001807
Aggression testosterone LLT C0001807
Aggression testosterone PT C0001807
Aggression testosterone LLT C0001807
Aggression testosterone PT C0001807
Agitation testosterone LLT C0085631
Agitation testosterone PT C0085631
Agitation testosterone PT C0085631
Agitation testosterone LLT C0085631
Agitation testosterone PT C0085631
Alanine aminotransferase increased testosterone LLT C0151905
Alanine aminotransferase increased testosterone PT C0151905
Allergic contact dermatitis testosterone LLT C0162820
Alopecia testosterone LLT C0002170
Alopecia testosterone PT C0002170
Alopecia testosterone LLT C0002170
Alopecia testosterone PT C0002170
Alopecia testosterone LLT C0002170
Alopecia testosterone PT C0002170
Alopecia testosterone LLT C0002170
Alopecia testosterone PT C0002170
Amenorrhoea testosterone LLT C0002453
Amenorrhoea testosterone PT C0002453
Amenorrhoea testosterone LLT C0002453
Amenorrhoea testosterone PT C0002453
Amnesia testosterone LLT C0002622
Amnesia testosterone PT C0002622
Anaemia testosterone LLT C0002871
Anaemia testosterone PT C0002871
Anaphylactic shock testosterone LLT C0002792
Anaphylactic shock testosterone PT C0002792
Anaphylactic shock testosterone PT C0002792
Anaphylactic shock testosterone PT C0002792
Anaphylactic shock testosterone PT C0002792
Anaphylactic shock testosterone LLT C0002792
Anaphylactic shock testosterone PT C0002792
Anaphylactic shock testosterone PT C0002792
Anaphylactoid reaction testosterone LLT C0340865
Anaphylactoid reaction testosterone PT C0340865
Anaphylactoid reaction testosterone LLT C0340865
Anaphylactoid reaction testosterone PT C0340865
Anaphylactoid reaction testosterone LLT C0340865
Anaphylactoid reaction testosterone PT C0340865
Anaphylactoid reaction testosterone LLT C0340865
Anaphylactoid reaction testosterone PT C0340865
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Testosterone used for in pharmaceutical contexts?

Testosterone (CAS 58-22-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Testosterone?

Testosterone has 2,892 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Blood testosterone decreased, Blood testosterone increased, Product deposit, Polycythaemia, Idiopathic intracranial hypertension. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Testosterone also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Testosterone with EU status "prohibited".

What clinical phase is Testosterone in?

Testosterone is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Testosterone?

Testosterone has 19 bioactivity rows in this page query. Rendered target entries include Sigma non-opioid intracellular receptor 1, Glucocorticoid receptor, Androgen receptor, Aromatase, Corticosteroid-binding globulin.